Skip to main content
. 2017 May 23;12(8):1291–1300. doi: 10.2215/CJN.05300516

Figure 3.

Figure 3.

Long-term eplerenone administration effect on renal function and tubulo-interstitial fibrosis. (A) Serum creatinine, (B) eGFR by the Zappitelli formula, (C) urinary albumin-to-creatinine ratio, and (D) percentage of tubulo-interstitial fibrosis assessed by morphometry analysis in placebo- (○) or eplerenone-treated patients (■). The data are expressed as mean±SD, except for urinary albumin-to-creatinine ratio expressed as median and 25th–75th percentiles. Alb/Cr, albumine/creatinine ratio; Ep0, eplerenone month 0; Ep6, eplerenone month 6; Ep12, eplerenone month 12; Ep24, eplerenone month 24; P0, placebo month 0; P6, placebo month 6; P12, placebo month 12; P24, placebo month 24.